Novel treatment approaches for locally advanced pancreatic cancer

Journal of the Pancreas

Volumn 15, Issue 2, 2014, Pages 95-98

  Gorovets, Daniel ^a   Saif, Muhammad Wasif ^a   Huber, Kathryn ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Genes; Pancreatic neoplasms; Radiosurgery; Ras

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; SMALL INTERFERING RNA; TIPIFARNIB;

ADVANCED CANCER; CONFERENCE PAPER; GENE MUTATION; HUMAN; ONCOGENE K RAS; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); STEREOTACTIC BODY RADIATION THERAPY; SYMPOSIUM;

EID: 84897911419     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: 10.6092/1590-8577%2F2284     Document Type: Conference Paper

References (16)

1. American Cancer Society. Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013.
2. Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007 Jan 20;25(3):326-31. [PMID: 17235048].
3. Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, phase 2 trial. Lancet Oncol. 2013 Apr;14(4):317-26. [PMID: 23474363].
4. Hammel P, Huguet F, Van Laethem JL, Goldstein D, Glimelius B, et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. J Clin Oncol 31,2013 (suppl; abstr #LBA4003).
5. Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009 Feb 1;115(3):665-72. [PMID: 19117351].
6. Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM, et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):181-8. [PMID: 21549517].
7. Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, et al. Unresectable locally advanced pancreatic cancer: A multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol. 2010 Aug;17(8):2092-101. [PMID:20224860].
8. Rwigema JC, Parikh SD, Heron DE, Howell M, Zeh H, Moser AJ, et al. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol. 2011 Feb;34(1):63-9. [PMID: 20308870].
9. Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):516-22. [PMID: 23562768].
10. Pollom EL, Alagappan M, Chan C, Shultz D, Kunz PL, Koong A, et al. Outcomes and toxicity of SBRT for patients with unresectable pancreatic adenocarcinoma. J Clin Oncol 32, 2014 (suppl 3; abstr 317).
11. Moningi S, Raman SP, Dholakia AS, Hacker-Prietz A, Pawlik TM, Zheng L, et al. Stereotactic body radiation therapy for pancreatic cancer: Single institutional experience. J Clin Oncol 32, 2014 (suppl 3; abstr 328).
12. Gurka MK, Kim CM, Haddad NG, Carroll J, Charabaty AC, Jackson PG, et al. Stereotactic body radiation therapy (SBRT) combined with chemotherapy for locally advanced pancreatic adenocarcinoma. J Clin Oncol 32, 2014 (suppl 3; abstr 361).
13. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004 Apr 15;22(8):1430-8. [PMID: 15084616].
14. Fleming JB, Shen GL, Holloway SE, Davis M Brekken RA. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: Justification for K-ras-directed therapy. Mol Cancer Res. 2005 Jul;3(7):413-23. [PMID: 16046551].
15. Golan T, Hubert A, Shemi A, Segal A, Khvalevsky EZ, Domb A, et al. Novel K-ras-directed therapy in combination with chemotherapy for locally advanced pancreatic adenocarcinoma. J Clin Oncol 32, 2014 (suppl 3; abstr 270).
16. Brunner TB, Cengel KA, Hahn SM, Wu J, Fraker DL, McKenna WG, et al. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: The role of K-ras. Cancer Res. 2005 Sep 15;65(18):8433-41. [PMID: 16166322].